gabapentin and Action Tremor studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

Excerpt	Relevance	Reference
"At day 15, both gabapentin and propranolol demonstrated significant and comparable efficacy in reducing tremor from baseline in all tremor measures."	9.09	A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. ( Barbanoj, M; Gironell, A; Hernández, G; Kulisevsky, J; López-Villegas, D; Pascual-Sedano, B, 1999)
"Gabapentin has been reported to be effective for essential tremor (ET) based on open-label trials."	9.08	Double-blind controlled trial of gabapentin in essential tremor. ( Busenbark, K; Hubble, JP; Koller, WC; Lyons, K; Pahwa, A; Pahwa, R; Rienerth, JD, 1998)
"Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated."	9.08	Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998)
"We treated four patients affected by orthostatic tremor (OT) with gabapentin in increasing doses (300 to 2,400 mg/d)."	9.08	Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients. ( D'Andreamatteo, G; Onofrj, M; Paci, C; Thomas, A, 1998)
"To review the use of the antiepileptic drug gabapentin for the treatment of various types of tremor."	8.82	Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003)
"We describe a 76-year-old patient with a severe tremor due to chronic demyelinating neuropathy associated with a benign IgM paraproteinaemia that was successfully treated with gabapentin."	7.71	Tremor associated with benign IgM paraproteinaemic neuropathy successfully treated with gabapentin. ( Abbruzzese, G; Capello, E; Saverino, A; Schenone, A; Solaro, C; Trompetto, C, 2001)
"We report seven patients with orthostatic tremor (OT) who were successfully treated with the anticonvulsant gabapentin."	7.70	Effective treatment of orthostatic tremor with gabapentin. ( Adler, CH; Caviness, JN; Evidente, VG; Gwinn, KA, 1998)
"Primary orthostatic tremor (OT) is a rare but disabling condition characterized by leg tremor and feelings of instability during stance."	6.72	Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006)
"Primary orthostatic tremor (OT) is characterized by leg tremor and instability on standing."	6.71	Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, G; Walters, SE, 2005)
"At day 15, both gabapentin and propranolol demonstrated significant and comparable efficacy in reducing tremor from baseline in all tremor measures."	5.09	A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. ( Barbanoj, M; Gironell, A; Hernández, G; Kulisevsky, J; López-Villegas, D; Pascual-Sedano, B, 1999)
"This study demonstrates that gabapentin improves rigidity, bradykinesia, and tremor of parkinsonism including both Parkinson's disease and Parkinson's syndrome."	5.08	Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. ( Gruenthal, M; Mueller, ME; Olson, WH; Olson, WL, 1997)
"Gabapentin has been reported to be effective for essential tremor (ET) based on open-label trials."	5.08	Double-blind controlled trial of gabapentin in essential tremor. ( Busenbark, K; Hubble, JP; Koller, WC; Lyons, K; Pahwa, A; Pahwa, R; Rienerth, JD, 1998)
"Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated."	5.08	Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998)
"We treated four patients affected by orthostatic tremor (OT) with gabapentin in increasing doses (300 to 2,400 mg/d)."	5.08	Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients. ( D'Andreamatteo, G; Onofrj, M; Paci, C; Thomas, A, 1998)
"To review the use of the antiepileptic drug gabapentin for the treatment of various types of tremor."	4.82	Gabapentin for the treatment of tremor. ( Bertoni, JM; Faulkner, MA; Lenz, TL, 2003)
"We describe a 76-year-old patient with a severe tremor due to chronic demyelinating neuropathy associated with a benign IgM paraproteinaemia that was successfully treated with gabapentin."	3.71	Tremor associated with benign IgM paraproteinaemic neuropathy successfully treated with gabapentin. ( Abbruzzese, G; Capello, E; Saverino, A; Schenone, A; Solaro, C; Trompetto, C, 2001)
"We report seven patients with orthostatic tremor (OT) who were successfully treated with the anticonvulsant gabapentin."	3.70	Effective treatment of orthostatic tremor with gabapentin. ( Adler, CH; Caviness, JN; Evidente, VG; Gwinn, KA, 1998)
"Primary orthostatic tremor (OT) is a rare but disabling condition characterized by leg tremor and feelings of instability during stance."	2.72	Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006)
"Primary orthostatic tremor (OT) is characterized by leg tremor and instability on standing."	2.71	Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, G; Walters, SE, 2005)
"Dystonic limb tremor may respond to anticholinergics."	2.50	The treatment of tremor. ( Deuschl, G; Schneider, SA, 2014)
"In our population of orthostatic tremor patients, mild postural hand tremor was a frequent finding."	2.50	Orthostatic tremor: a review of 45 cases. ( Ondo, WG; Yaltho, TC, 2014)
"Monosymptomatic rest tremor has recently been shown to be associated with decreased fluorodopa uptake on the positron emission tomography scan suggesting its relationship to Parkinson disease."	2.42	Tremor. ( Sethi, KD, 2003)
"Parkinson's disease is a neurodegenerative disorder that manifests clinically with variable degrees of tremor, muscle rigidity, bradykinesia and postural instability."	2.41	Tremor-predominant Parkinson's disease. Approaches to treatment. ( Koller, W; Marjama-Lyons, J, 2000)
"Essential tremor is the most prevalent adult-onset movement disorder, and is also regarded as one of the most common neurological disorders of adults, with a prevalence that is similar to or greater than that of stroke, Alzheimer disease, migraine headache, and lumbosacral pain syndromes."	2.40	A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor. ( Louis, ED, 1999)
"Treatment with gabapentin was initiated for OPT presumed secondary to neuro-Behçet disease."	1.42	Neuro-Behçet disease presenting with oculopalatal tremor. ( Espino Barros Palau, A; Foroozan, R; Lee, AG; Morgan, ML, 2015)
"All the patients had repetitive myoclonus of all limbs, impairing gait in 14 patients."	1.34	Whole-body tremulousness: isolated generalized polymyoclonus. ( Ahlskog, JE; Bower, JH; Glass, GA; Josephs, KA; Lennon, VA; McKeon, A; Pittock, SJ, 2007)
"Gabapentin is an antiepileptic agent that is indicated for use as adjunctive therapy for partial seizures."	1.30	A case of sustained massive gabapentin overdose without serious side effects. ( Radtke, RA; St Clair, EW; Verma, A, 1999)

Research

Studies (24)

Authors

Clinical Trials (3)

Trial Overview

Trial Outcomes

"Change From Baseline in the Standard Deviation of the Lateral Position (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®"

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (33.33)	18.2507
2000's	9 (37.50)	29.6817
2010's	6 (25.00)	24.3611
2020's	1 (4.17)	2.80

Authors	Studies
Theeranaew, W	1
Thurtell, MJ	1
Loparo, K	1
Shaikh, AG	1
Schmidt, P	1
Rao, S	1
Schneider, SA	1
Deuschl, G	1
Yaltho, TC	1
Ondo, WG	1
Morgan, ML	1
Espino Barros Palau, A	1
Lee, AG	1
Foroozan, R	1
Struble, LM	1
Faulkner, MA	1
Bertoni, JM	1
Lenz, TL	1
Sethi, KD	1
Rodrigues, JP	2
Edwards, DJ	2
Walters, SE	2
Byrnes, ML	2
Thickbroom, G	1
Stell, R	2
Mastaglia, FL	2
Thickbroom, GW	1
Platt, SR	1
De Stefani, A	1
Wieczorek, L	1
Striano, P	1
Coppola, A	1
Madia, F	1
Pezzella, M	1
Ciampa, C	1
Zara, F	1
Striano, S	1
McKeon, A	1
Pittock, SJ	1
Glass, GA	1
Josephs, KA	1
Bower, JH	1
Lennon, VA	1
Ahlskog, JE	1
Olson, WL	1
Gruenthal, M	1
Mueller, ME	1
Olson, WH	1
Pahwa, R	1
Lyons, K	1
Hubble, JP	1
Busenbark, K	1
Rienerth, JD	1
Pahwa, A	1
Koller, WC	1
Merren, MD	1
Onofrj, M	1
Thomas, A	1
Paci, C	1
D'Andreamatteo, G	1
Evidente, VG	1
Adler, CH	1
Caviness, JN	1
Gwinn, KA	1
Gironell, A	1
Kulisevsky, J	1
Barbanoj, M	1
López-Villegas, D	1
Hernández, G	1
Pascual-Sedano, B	1
Louis, ED	1
Verma, A	1
St Clair, EW	1
Radtke, RA	1
Marjama-Lyons, J	1
Koller, W	1
Saverino, A	1
Solaro, C	1
Capello, E	1
Trompetto, C	1
Abbruzzese, G	1
Schenone, A	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 4, Double-Blind, Placebo-Controlled, Crossover Study Comparing Simulated Driving Performance, Daytime Sedation, and Cognition in Healthy Volunteers Taking Therapeutic Doses of Gralise®, Neurontin®, or Lyrica®[NCT03179345]	Phase 4	32 participants (Actual)	Interventional	2015-09-24	Completed
A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome.[NCT00533455]	Phase 3	40 participants (Anticipated)	Interventional	2004-03-31	Terminated (stopped due to Failure to recruit due to polypharmacy)
Environmental Epidemiology of Essential Tremor[NCT04576676]		1,497 participants (Actual)	Observational	2020-07-02	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

"Change From Baseline in the Standard Deviation of the Lateral Position (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®"

Intervention	feet (Least Squares Mean)
Gralise® (Gabapentin)	0.255
Lyrica® (Pregabalin)	0.356
Placebo	0.135

SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).

Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)

Intervention	feet (Least Squares Mean)
Gralise® (Gabapentin)	0.255
Neurontin® (Gabapentin)	0.395
Placebo	0.135

Intervention	mph (Least Squares Mean)
Gralise® (Gabapentin)	0.831
Lyrica® (Pregabalin)	1.319
Placebo	0.851

Intervention	mph (Least Squares Mean)
Gralise® (Gabapentin)	0.831
Neurontin® (Gabapentin)	0.947
Placebo	0.851

Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).

Intervention	msec (Least Squares Mean)
Gralise® (Gabapentin)	0.00
Neurontin® (Gabapentin)	0.00
Lyrica® (Pregabalin)	-0.01
Placebo (Sugar Pill)	-0.00

Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).

Intervention	Number of errors on test (Least Squares Mean)
Gralise® (Gabapentin)	-0.40
Neurontin® (Gabapentin)	-0.01
Lyrica® (Pregabalin)	-0.64
Placebo (Sugar Pill)	3.32

Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)

Intervention	Score on Scale (Least Squares Mean)
Gralise® (Gabapentin)	-0.00
Neurontin® (Gabapentin)	0.00
Lyrica® (Pregabalin)	-0.00
Placebo (Sugar Pill)	0.01

Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).

Intervention	Score on Scale (Least Squares Mean)
Gralise® (Gabapentin)	0.36
Neurontin® (Gabapentin)	0.82
Lyrica® (Pregabalin)	0.03
Placebo (Sugar Pill)	-0.01

Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).

Intervention	Score on Scale (Least Squares Mean)
Gralise® (Gabapentin)	0.02
Neurontin® (Gabapentin)	0.06
Lyrica® (Pregabalin)	0.00
Placebo (Sugar Pill)	0.03

Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).

Intervention	units on a scale (Least Squares Mean)
Gralise® (Gabapentin)	.774
Neurontin® (Gabapentin)	.264
Lyrica® (Pregabalin)	.868
Placebo (Sugar Pill)	.264

Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. [1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints. (NCT03179345)
Timeframe: Baseline and Hour 3 on Day 3

To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.

Intervention	scores on a scale (Least Squares Mean)
	Vision (blurring, double vision)	Energy Level (get up and go)	Memory (ability to remember people, places, or thi	Walking (balance)	Interest (in activities)	Coordination	Tremor (shakiness)	Concentration (ability to concentrate on a task)	Speech (slurring words)	Forgetfulness	Sleepiness (fatigue, sedation, tiredness)	Moodiness	Alertness	Attention Span	Motivation
Gralise® (Gabapentin)	0.036	0.099	0.077	0.206	0.046	0.180	-0.103	0.080	0.035	0.118	0.693	0.181	0.297	0.020	0.185
Lyrica® (Pregabalin)	0.249	0.315	0.125	0.405	0.096	0.350	-0.031	0.137	0.065	0.175	1.176	0.098	0.607	0.146	0.368
Neurontin® (Gabapentin)	0.322	0.256	0.123	0.327	0.030	0.392	0.037	0.164	0.133	0.227	0.635	0.163	0.451	0.133	0.232
Placebo (Sugar Pill)	0.115	0.331	-0.041	0.107	0.070	0.218	0.068	0.182	0.103	0.079	0.541	0.100	0.353	0.015	0.271

"Number of subjects with Treatment-Emergent Adverse Events (TEAE)~Number of subjects with Serious Adverse Event (SAE)~Number of subjects discontinued due to Adverse Event (AE)" (NCT03179345)
Timeframe: Screening to 1 week after Period 4 discharge

Article	Year
The treatment of tremor. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2014, Volume: 11, Issue:1 Topics: Amines; Anticonvulsants; Botulinum Toxins; Cyclohexanecarboxylic Acids; Deep Brain Stimulation; Fruc	2014
Orthostatic tremor: a review of 45 cases. Parkinsonism & related disorders, 2014, Volume: 20, Issue:7 Topics: Adult; Aged; Amines; Clonazepam; Cyclohexanecarboxylic Acids; Deep Brain Stimulation; Dizziness; Fem	2014
Tremors: learning to stop the shakes. The Nurse practitioner, 2010, Volume: 35, Issue:6 Topics: Adrenergic beta-Antagonists; Alprazolam; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabap	2010
Gabapentin for the treatment of tremor. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:2 Topics: Acetates; Adult; Aged; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Gabapentin; ga	2003
Tremor. Current opinion in neurology, 2003, Volume: 16, Issue:4 Topics: Acetates; Amines; Anticonvulsants; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Diagnosis, Dif	2003
A new twist for stopping the shakes? Revisiting GABAergic therapy for essential tremor. Archives of neurology, 1999, Volume: 56, Issue:7 Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; GABA Agonists; Gabapentin; gamma-Aminobutyric	1999
Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs & aging, 2000, Volume: 16, Issue:4 Topics: Acetates; Amantadine; Amines; Antiparkinson Agents; Botulinum Toxins; Cholinergic Antagonists; Clona	2000

Article	Year
Effects of gabapentin, pregabalin and gastroretentive gabapentin on simulated driving, daytime sedation and cognition. Pain management, 2018, Jul-01, Volume: 8, Issue:4 Topics: Adult; Amines; Analgesics; Attention; Automobile Driving; Cognition; Cyclohexanecarboxylic Acids; Fe	2018
Gabapentin can improve postural stability and quality of life in primary orthostatic tremor. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:7 Topics: Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Electromyography; Female; Gabapentin; ga	2005
Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:7 Topics: Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Doub	2006
Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. The American journal of medicine, 1997, Volume: 102, Issue:1 Topics: Acetates; Adult; Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids	1997
Double-blind controlled trial of gabapentin in essential tremor. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:3 Topics: Acetates; Activities of Daily Living; Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acid	1998
Gabapentin for treatment of pain and tremor: a large case series. Southern medical journal, 1998, Volume: 91, Issue:8 Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc	1998
Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients. Neurology, 1998, Volume: 51, Issue:3 Topics: Acetates; Aged; Amines; Anticonvulsants; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Bli	1998
A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Archives of neurology, 1999, Volume: 56, Issue:4 Topics: Acetates; Administration, Oral; Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanec	1999

Article	Year
Gabapentin and memantine increases randomness of oscillatory waveform in ocular palatal tremor. Journal of computational neuroscience, 2021, Volume: 49, Issue:3 Topics: Eye Movements; Gabapentin; Humans; Memantine; Models, Neurological; Tremor	2021
Add-on Gabapentin Alleviates Paliperidone-induced Head Tremors and\ Boosts Antipsychotic Response in Early-Onset Schizophrenia Israel journal of psychiatry, 2017, Dec-01, Volume: 54, Issue:2 Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Drug Therapy, Combination; Gabapentin; Head Movem	2017
Neuro-Behçet disease presenting with oculopalatal tremor. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2015, Volume: 35, Issue:1 Topics: Adult; Amines; Anticonvulsants; Behcet Syndrome; Cyclohexanecarboxylic Acids; Female; Gabapentin; ga	2015
Primary orthostatic tremor in a Scottish deerhound. The Veterinary record, 2006, Oct-07, Volume: 159, Issue:15 Topics: Amines; Animals; Cyclohexanecarboxylic Acids; Dog Diseases; Dogs; Electromyography; Excitatory Amino	2006
Life-threatening status epilepticus following gabapentin administration in a patient with benign adult familial myoclonic epilepsy. Epilepsia, 2007, Volume: 48, Issue:10 Topics: Acute Disease; Amines; Anticonvulsants; Benzodiazepines; Cyclohexanecarboxylic Acids; Drug Resistanc	2007
Whole-body tremulousness: isolated generalized polymyoclonus. Archives of neurology, 2007, Volume: 64, Issue:9 Topics: Adult; Aged; Amines; Anticonvulsants; Autoimmunity; Breast Neoplasms; Clonazepam; Cyclohexanecarboxy	2007
Effective treatment of orthostatic tremor with gabapentin. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:5 Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr	1998
A case of sustained massive gabapentin overdose without serious side effects. Therapeutic drug monitoring, 1999, Volume: 21, Issue:6 Topics: Acetates; Adult; Amines; Anticonvulsants; Cognition; Cyclohexanecarboxylic Acids; Drug Overdose; Epi	1999
Tremor associated with benign IgM paraproteinaemic neuropathy successfully treated with gabapentin. Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:5 Topics: Acetates; Aged; Amines; Antiparkinson Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma	2001

gabapentin and Action Tremor